• Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.¹ About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.²
• The VENTANA HER2 Dual ISH DNA Probe Cocktail assay³ aids in identifying breast and gastric cancer patients eligible for the targeted Roche drug Herceptin (trastuzumab), providing fast results with widely available laboratory instruments.
• This approval supports Roche’s personalized healthcare strategy to provide treatment to patients who can benefit most from a specific medicine.

Continue reading→

Recent research suggests our gut microbiomes affect brain communication and neurological health. Worldwide, interest is growing in the idea that changes in normal gut microbiota may be responsible for triggering various conditions. At ASU, a research team is exploring using the microbiome to treat autism symptoms.

The team of ASU researchers, Rosa Krajmalnik-Brown, James Adams, and Dae Wook Kang, were inspired to explore the gut-brain connection as it relates to autism symptoms and gastrointestinal issues.
Continue reading→

Research by a Barrow Neurological Center scientist on mechanisms of dysfunctional RNA processing in ALS and frontaltemporal dementia (FTD) was published in the April issue of Acta Neuropathologica. The research was conducted by Dr. Rita Sattler and her graduate student Stephen Moore in her laboratory at the Department of Neurobiology at Barrow Neurological Institute, which is dedicated to understanding the mechanisms of disease in ALS, FTD and related neurodegenerative diseases.Continue reading→

Investment to advance drug discovery, medicine and renewable energyContinue reading→

HonorHealth Research Institute announced that the first patients have been enrolled in the SynIVUS-DAPT Study, a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet medications after receiving a drug-eluting coronary stent.Continue reading→

Twenty of Arizona’s highest-achieving high-school seniors have been named Flinn Scholars and will receive scholarships to Arizona’s three public research universities valued at more than $120,000.Continue reading→

PHOENIX, April 15, 2019 — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company.Continue reading→

Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards, which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.Continue reading→